{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:09:22Z","timestamp":1791922162330,"version":"4.3.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the pharmacokinetics, efficacy, and safety of recently approved calcipotriene and betamethasone dipropionate (C-BD) cream.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>A literature review was conducted using MEDLINE (PubMed) and ClinicalTrials.gov from 2002 to mid-May 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction<\/jats:title>\n                    <jats:p>Articles in English discussing the use of C-BD cream in the treatment of psoriasis were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis<\/jats:title>\n                    <jats:p>In 2 phase I trials, there was no phototoxic or photoallergic skin reaction at irradiated C-BD cream sites at baseline, 24 hours, 48 hours, and 72 hours postirradiation. In 2 phase III trials, after 8 weeks of treatment, more subjects treated with C-BD cream achieved Physician\u2019s Global Assessment treatment success (37.4%), compared to C-BD topical suspension (TS) (22.8%, P &lt; 0.0001) and vehicle (3.7%, P &lt; 0.0001). More subjects had greater mean percentage decline in Modified Psoriasis Area Severity Index (Trial 1: 52.9% and Trial 2: 64.6%), when compared to C-BD TS (Trial 1: 51.3%, P &lt; 0.0001 and Trial 2: 56.4%, P &lt; 0.0001) and vehicle (Trial 1: 22.9%, P &lt; 0.0001 and Trial 2: 20.0%, P &lt; 0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice<\/jats:title>\n                    <jats:p>Psoriasis has a multifactorial pathogenesis and topical treatments are considered first line. Poor adherence is a major hurdle in management; the combination of 2 separate first-line drugs may address this by decreasing the complexity of treatment regimens. A cream formulation can be preferred, and C-BD is now Food and Drug Administration (FDA) approved as one.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Newly FDA-approved C-BD cream with novel polyaphron dispersion (PAD) technology provides a safe efficacious combination therapy for mild-to-moderate psoriasis which may be preferred by some patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221105508","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T03:29:27Z","timestamp":1655868567000},"page":"341-347","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-4013","authenticated-orcid":false,"given":"Alexandra","family":"Taylor","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-1639","authenticated-orcid":false,"given":"Rohan","family":"Singh","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"bibr1-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1717417."},{"key":"bibr2-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.122755."},{"key":"bibr3-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-62."},{"key":"bibr4-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.914437."},{"issue":"4","key":"bibr5-10600280221105508","first-page":"278","volume":"63","author":"Kim WB","year":"2017","journal-title":"Can Fam Physician"},{"key":"bibr6-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006."},{"key":"bibr7-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005028.pub2."},{"key":"bibr8-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.028."},{"key":"bibr9-10600280221105508","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5653."},{"key":"bibr10-10600280221105508","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101539."},{"key":"bibr11-10600280221105508","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION: WYNZORATM (calcipotriene and betamethasone dipropionate cream). Accessed February 26, 2022. www.fda.gov\/medwatch."},{"key":"bibr12-10600280221105508","unstructured":"MC2 therapeutics\u2014PADTM cream\u2014platform. Accessed February 27, 2022. https:\/\/mc2therapeutics.com\/platform-2\/."},{"key":"bibr13-10600280221105508","unstructured":"Wynzora 50 micrograms\/g + 0.5mg\/g cream\u2014summary of product characteristics (SmPC)\u2014(emc). Accessed March 1, 2022. https:\/\/www.medicines.org.uk\/emc\/product\/13200\/smpc#gref."},{"key":"bibr14-10600280221105508","doi-asserted-by":"publisher","DOI":"10.4187\/RESPCARE.06314."},{"key":"bibr15-10600280221105508","unstructured":"Evaluation of the vasoconstriction properties of MC2-01 cream\u2014full text view. ClinicalTrials.gov. Accessed March 1, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03758365?term=MC2-01+Cream&draw=2&rank=7."},{"key":"bibr16-10600280221105508","unstructured":"A maximal use trial evaluating the pharmacokinetic profile of MC2-01 cream in adolescent subjects\u2014study results. ClinicalTrials.gov. Accessed March 6, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03819218?term=MC2-01+Cream&draw=2&rank=1."},{"key":"bibr17-10600280221105508","unstructured":"A maximal use trial evaluating the pharmacokinetic profile of MC2-01 cream\u2014full text view. ClinicalTrials.gov. Accessed March 1, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03462927?term=MC2-01+Cream&draw=2&rank=3."},{"key":"bibr18-10600280221105508","unstructured":"Evaluation of potential development of photoallergic skin reaction after use of MC2-01 cream\u2014full text view. ClinicalTrials.gov. Accessed February 26, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03899064?term=MC2-01+Cream&draw=2&rank=4."},{"key":"bibr19-10600280221105508","unstructured":"Evaluation of potential phototoxicity skin reaction after use of MC2-01 cream\u2014study results. ClinicalTrials.gov. Accessed February 26, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03892564?term=MC2-01+Cream&draw=2&rank=2."},{"key":"bibr20-10600280221105508","unstructured":"A clinical trial evaluating efficacy and safety of MC2-01 cream\u2014full text view. ClinicalTrials.gov. Accessed February 26, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03308799?term=NCT03308799&draw=2&rank=1."},{"key":"bibr21-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17734."},{"key":"bibr22-10600280221105508","unstructured":"This trial is a randomised, multicentre, investigator-blind, vehicle and comparator-controlled, parallel-group trial with the purpose of evaluation efficacy, safety and convenience of the MC2-01 cream\u2014full text view. ClinicalTrials.gov. Accessed February 26, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03802344?term=MC2-01+Cream&draw=2&rank=6."},{"key":"bibr23-10600280221105508","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-018-1246-2."},{"key":"bibr24-10600280221105508","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2016.006."},{"key":"bibr25-10600280221105508","unstructured":"Betamethasone\/calcipotriene topical Prices, Coupons & Patient Assistance Programs. Drugs.com. Accessed February 28, 2022. https:\/\/www.drugs.com\/price-guide\/betamethasone-calcipotriene-topical."},{"key":"bibr26-10600280221105508","unstructured":"Prescription prices, coupons & pharmacy information. GoodRx. Accessed March 18, 2022. https:\/\/www.goodrx.com\/."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221105508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221105508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221105508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:56Z","timestamp":1777375016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221105508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/10600280221105508"],"URL":"https:\/\/doi.org\/10.1177\/10600280221105508","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}